Accelrys says biological registration systems are inherently more complex than existing chemical registration systems which are commonplace in the pharmaceutical industry.
In discussions with pharmaceutical companies, Accelrys has established that many organizations have struggled to solve this problem due to the dynamic nature of biological entities. The collaborative development model allows Accelrys to leverage the collective knowledge and expertise of the participants to establish requirements while using its platform technology to develop a solution.
Phase one of the collaborative software development effort includes identifying the requirements for the registration of biological entities. Accelrys expects additional pharmaceutical companies to join the effort in subsequent phases of the collaboration.
Mark Emkjer, Accelrys president and CEO, said: “Accelrys is a company with a rich history of collaborative software development with our customers. The development of the Biological Registration suite of database entities and applications is another example of how we are continually working to develop innovative scientific business intelligence solutions to provide expanded applications and commercialize those solutions for our broader customer base.”